The agency has expanded the use of Alyftrek and Trikafta for treating patients with any genetic variant that results in production of CFTR proteins.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved ...

Vertex Pharmaceuticals (VRTX) stock is in focus as the FDA greenlights label expansions for its cystic fibrosis drugs, ...

A decade of war in Ukraine has led to widespread PTSD, depression, and suicidal behavior in children, need for perceived ...

A medical research ecosystem that helped produce inspiring advances is in jeopardy, writes the Register's editorial board.

VRTX stock slips nearly 5% as concerns over new drug uptake and pipeline setbacks weigh, even as its dominant CF franchise continues to drive steady growth.

This clinical-stage biotech develops therapies targeting the root cause of cystic fibrosis, with a pipeline focused on CFTR modulators.

A new product approval may be right around the corner.

William O’Neal II was skeptical. He’d taken pills all his life and they'd had only ever moderately helped his myriad cystic fibrosis symptoms. Invasive nebulizer therapies and harsh mucus-loosening ...

Patients aged 6 years and older with cystic fibrosis will be able to access the triple combination treatment vanzacaftor/tezacaftor/deutivacaftor on NHS Scotland ...